Table 2

The effect on mortality of receiving VAS in a campaign, overall and by sex, campaign and age group

Rate per 1000 PYRS (deaths/PYRS)Crude MRR (95% CI)Adjusted MRR (95% CI)*
AllBoysGirlsAllBoysGirls
All
 VAS15.3 (44/2873)0.93 (0.55 to 1.58)0.85 (0.44 to 1.67)1.07 (0.45 to 2.57)0.78 (0.46 to 1.34)0.73 (0.37 to 1.43)0.89 (0.37 to 2.14)
 No VAS15.9 (20/1260)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)
 No information32.5 (8/227)2.17 (0.96 to 4.94)2.04 (0.73 to 5.71)2.40 (0.62 to 9.27)2.10 (0.75 to 5.89)1.96 (0.59 to 6.57)2.35 (0.53 to 10.4)
2007
 VAS4.4 (6/1352)0.40 (0.14 to 1.15)0.54 (0.15 to 1.85)0.18 (0.02 to 1.69)0.38 (0.13 to 1.10)0.52 (0.15 to 1.79)0.16 (0.02 to 1.59)
 No VAS10.9 (8/731)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)
2008
 VAS24.4 (38/1521)1.04 (0.54 to 2.00)0.88 (0.39 to 2.00)1.37 (0.46 to 4.09)1.02 (0.53 to 1.96)0.86 (0.38 to 1.96)1.32 (0.44 to 3.94)
 No VAS21.7 (12/529)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)
p For same effect of VAS in 2007 and 20090.130.510.110.120.500.11
Children aged 6–11 months
 VAS23.3 (16/687)1.35 (0.48 to 3.76)1.68 (0.47 to 6.07)0.84 (0.15 to 4.66)1.14 (0.41 to 3.19)1.41 (0.40 to 5.10)0.72 (0.13 to 3.98)
 No VAS17.0 (5/294)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)
Children aged 12–35 months
 VAS12.8 (28/2186)0.81 (0.43 to 1.51)0.62 (0.27 to 1.39)1.19 (0.43 to 3.30)0.69 (0.36 to 1.29)0.53 (0.23 to 1.20)0.98 (0.35 to 2.72)
 No VAS15.5 (15/966)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)1 (ref)
p For same effect of VAS in younger and older children0.400.200.740.410.210.76
  • * Adjusted for sex, campaign, seen vaccination card, ethnicity and maternal education.

  • MRR, mortality rate ratio; PYRS, person-years; VAS, vitamin A supplementation.